Now showing items 1-3 of 3

    • Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. 

      Abdool Karim, Quarraisha.; Kharsany, Ayesha B. M.; Naidoo, Kasavan.; Yende Zuma, Nonhlanhla.; Gengiah, Tanuja N.; Omar, Zaheen.; Arulappan, Natasha.; Mlisana, Koleka Patience.; Luthuli, Londiwe R.; Abdool Karim, Salim Safurdeen. (Elsevier., 2011-05)
      Background—In settings where multiple HIV prevention trials are conducted in close proximity, trial participants may attempt to enroll in more than one trial simultaneously. Co-enrollment impacts on participant’s safety ...
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Frohlich, Janet A.; Grobler, Anna Christina.; Baxter, Cheryl.; Mansoor, Leila E.; Kharsany, Ayesha B. M.; Sibeko, Sengeziwe.; Mlisana, Koleka Patience.; Omar, Zaheen.; Gengiah, Tanuja N.; Maarschalk, Silvia.; Arulappan, Natasha.; Mlotshwa, Mukelisiwe.; Morris, Lynn.; Taylor, Douglas. (American Association for the Advancement of Science., 2010-09)
      The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the ...
    • Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. 

      Abdool Karim, Quarraisha.; Kharsany, Ayesha B. M.; Frohlich, Janet A.; Baxter, Cheryl.; Yende Zuma, Nonhlanhla.; Mansoor, Leila E.; Mlisana, Koleka Patience.; Maarschalk, Silvia.; Arulappan, Natasha.; Grobler, Anna Christina.; Sibeko, Sengeziwe.; Omar, Zaheen.; Gengiah, Tanuja N.; Mlotshwa, Mukelisiwe.; Samsunder, Natasha.; Abdool Karim, Salim Safurdeen. (Biomed Central, 2011-03-07)
      Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap ...